Analysis of Liquidity Ratios
Quarterly Data
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Celgene Corp., liquidity ratios (quarterly data)
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Celgene Corp. current ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Celgene Corp. quick ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Celgene Corp. cash ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level. |
Current Ratio
Celgene Corp., current ratio calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Current assets | 14,454) | 12,683) | 10,981) | 9,067) | 7,827) | 6,853) | 7,872) | 14,892) | 14,783) | 13,136) | 11,617) | 10,868) | 9,576) | 9,169) | 8,386) | 9,401) | 10,152) | 9,884) | 9,665) | 9,713) | 8,836) | 8,107) | 6,942) | |||||||
| Current liabilities | 5,009) | 3,685) | 3,955) | 4,057) | 3,683) | 4,502) | 3,115) | 2,987) | 4,049) | 3,240) | 2,629) | 2,959) | 2,649) | 1,987) | 1,834) | 1,969) | 3,144) | 2,960) | 2,097) | 2,112) | 1,398) | 1,492) | 2,425) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Current ratio1 | 2.89 | 3.44 | 2.78 | 2.23 | 2.13 | 1.52 | 2.53 | 4.99 | 3.65 | 4.05 | 4.42 | 3.67 | 3.61 | 4.61 | 4.57 | 4.77 | 3.23 | 3.34 | 4.61 | 4.60 | 6.32 | 5.44 | 2.86 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Current Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 1.15 | 0.89 | 1.04 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 2.89 | 2.89 | 2.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.83 | 3.88 | 1.93 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 3.43 | 2.32 | 2.18 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 1.17 | 1.13 | 1.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.96 | 3.76 | 3.62 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 1.26 | 1.33 | 1.44 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 1.26 | 1.21 | 1.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 7.40 | 6.77 | 7.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.90 | 1.47 | 1.54 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 4.03 | 3.88 | 4.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 1.80 | 1.49 | 1.69 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
1 Q3 2019 Calculation
Current ratio = Current assets ÷ Current liabilities
= 14,454 ÷ 5,009 = 2.89
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Celgene Corp. current ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level. |
Quick Ratio
Celgene Corp., quick ratio calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cash and cash equivalents | 9,604) | 7,214) | 5,433) | 4,234) | 2,480) | 1,503) | 2,819) | 7,013) | 5,511) | 6,660) | 5,273) | 6,170) | 5,523) | 5,064) | 4,446) | 4,880) | 6,017) | 4,531) | 4,368) | 4,122) | 3,743) | 3,220) | 2,397) | |||||||
| Debt securities available-for-sale | 14) | 613) | 664) | 496) | 66) | 79) | 68) | 3,219) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Equity investments with readily determinable fair values | 1,279) | 1,496) | 1,594) | 1,312) | 1,832) | 1,828) | 1,853) | 1,810) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Marketable securities available-for-sale | —) | —) | —) | —) | —) | —) | —) | —) | 6,248) | 3,480) | 3,588) | 1,800) | 1,346) | 1,340) | 1,262) | 1,672) | 1,489) | 2,961) | 2,946) | 3,425) | 3,118) | 2,994) | 2,714) | |||||||
| Accounts receivable, net of allowances | 2,374) | 2,451) | 2,327) | 2,066) | 2,120) | 2,064) | 1,991) | 1,921) | 1,816) | 1,729) | 1,614) | 1,621) | 1,586) | 1,515) | 1,420) | 1,421) | 1,272) | 1,273) | 1,179) | 1,167) | 1,068) | 1,124) | 1,073) | |||||||
| Total quick assets | 13,271) | 11,774) | 10,018) | 8,108) | 6,498) | 5,474) | 6,731) | 13,963) | 13,575) | 11,869) | 10,475) | 9,590) | 8,455) | 7,919) | 7,128) | 7,973) | 8,778) | 8,766) | 8,493) | 8,713) | 7,929) | 7,337) | 6,183) | |||||||
| Current liabilities | 5,009) | 3,685) | 3,955) | 4,057) | 3,683) | 4,502) | 3,115) | 2,987) | 4,049) | 3,240) | 2,629) | 2,959) | 2,649) | 1,987) | 1,834) | 1,969) | 3,144) | 2,960) | 2,097) | 2,112) | 1,398) | 1,492) | 2,425) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Quick ratio1 | 2.65 | 3.20 | 2.53 | 2.00 | 1.76 | 1.22 | 2.16 | 4.67 | 3.35 | 3.66 | 3.98 | 3.24 | 3.19 | 3.99 | 3.89 | 4.05 | 2.79 | 2.96 | 4.05 | 4.13 | 5.67 | 4.92 | 2.55 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.92 | 0.64 | 0.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 2.28 | 2.41 | 2.37 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.63 | 3.61 | 1.64 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 2.99 | 1.78 | 1.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.66 | 0.67 | 0.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.74 | 3.41 | 3.32 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.93 | 0.95 | 1.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.80 | 0.75 | 0.88 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 7.22 | 6.64 | 7.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.50 | 0.71 | 0.72 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 3.14 | 2.99 | 3.66 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.97 | 0.85 | 0.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
1 Q3 2019 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 13,271 ÷ 5,009 = 2.65
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Celgene Corp. quick ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level. |
Cash Ratio
Celgene Corp., cash ratio calculation (quarterly data)
| Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||||
| Cash and cash equivalents | 9,604) | 7,214) | 5,433) | 4,234) | 2,480) | 1,503) | 2,819) | 7,013) | 5,511) | 6,660) | 5,273) | 6,170) | 5,523) | 5,064) | 4,446) | 4,880) | 6,017) | 4,531) | 4,368) | 4,122) | 3,743) | 3,220) | 2,397) | |||||||
| Debt securities available-for-sale | 14) | 613) | 664) | 496) | 66) | 79) | 68) | 3,219) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Equity investments with readily determinable fair values | 1,279) | 1,496) | 1,594) | 1,312) | 1,832) | 1,828) | 1,853) | 1,810) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | —) | |||||||
| Marketable securities available-for-sale | —) | —) | —) | —) | —) | —) | —) | —) | 6,248) | 3,480) | 3,588) | 1,800) | 1,346) | 1,340) | 1,262) | 1,672) | 1,489) | 2,961) | 2,946) | 3,425) | 3,118) | 2,994) | 2,714) | |||||||
| Total cash assets | 10,897) | 9,323) | 7,691) | 6,042) | 4,378) | 3,410) | 4,740) | 12,042) | 11,759) | 10,140) | 8,861) | 7,970) | 6,869) | 6,404) | 5,707) | 6,552) | 7,506) | 7,492) | 7,314) | 7,547) | 6,861) | 6,213) | 5,110) | |||||||
| Current liabilities | 5,009) | 3,685) | 3,955) | 4,057) | 3,683) | 4,502) | 3,115) | 2,987) | 4,049) | 3,240) | 2,629) | 2,959) | 2,649) | 1,987) | 1,834) | 1,969) | 3,144) | 2,960) | 2,097) | 2,112) | 1,398) | 1,492) | 2,425) | |||||||
| Liquidity Ratio | ||||||||||||||||||||||||||||||
| Cash ratio1 | 2.18 | 2.53 | 1.94 | 1.49 | 1.19 | 0.76 | 1.52 | 4.03 | 2.90 | 3.13 | 3.37 | 2.69 | 2.59 | 3.22 | 3.11 | 3.33 | 2.39 | 2.53 | 3.49 | 3.57 | 4.91 | 4.17 | 2.11 | |||||||
| Benchmarks | ||||||||||||||||||||||||||||||
| Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||||
| AbbVie Inc. | 0.61 | 0.32 | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Amgen Inc. | 1.94 | 2.05 | 2.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 3.10 | 3.02 | 0.99 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Danaher Corp. | 2.40 | 1.08 | 0.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Eli Lilly & Co. | 0.15 | 0.20 | 0.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Gilead Sciences Inc. | 2.39 | 3.03 | 2.97 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Johnson & Johnson | 0.51 | 0.49 | 0.53 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Merck & Co. Inc. | 0.39 | 0.35 | 0.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Moderna Inc. | 7.16 | 6.61 | 6.97 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Pfizer Inc. | 0.25 | 0.40 | 0.39 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 1.63 | 1.56 | 2.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
| Thermo Fisher Scientific Inc. | 0.22 | 0.30 | 0.19 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |||||||
Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).
1 Q3 2019 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 10,897 ÷ 5,009 = 2.18
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Celgene Corp. cash ratio improved from Q1 2019 to Q2 2019 but then slightly deteriorated from Q2 2019 to Q3 2019 not reaching Q1 2019 level. |